{"id":"hum0561","version":1,"url":"https://humandbs.dbcls.jp/research/hum0561/v1","datePublished":"2026-05-26","versions":[{"version":1,"datePublished":"2026-05-26"}],"title":{"ja":"エンザルタミドの投与を受けている転移性去勢感受性前立腺癌（mCSPC）患者における癌ゲノムと臨床転帰の関連について検討する多施設前向き研究","en":"A Prospective Multicenter Study of Exploring Genomic Correlates of Clinical Outcome in Patients with Metastatic Castration-Sensitive Prostate Cancer Receiving Enzalutamide"},"summary":{"aims":{"ja":"経口非ステロイド性抗アンドロゲン剤であるエンザルタミドの投与を受けた転移性去勢感受性前立腺がん（Metastatic Castration-Sensitive Prostate Cancer：mCSPC）症例におけるがんゲノムと臨床転帰（臨床・画像上の無増悪生存期間、PSA低下、PSA無再発期間、全生存期間、CRPC進行までの期間、等）の関連についての検討を行う。本研究により得られる成果は、前立腺がんの個別化医療に向けた新たな治療戦略の創出につながる。","en":"The association between tumor genomic alterations and clinical outcomes, including clinical and radiographic progression-free survival, PSA response, PSA progression-free survival, overall survival, and time to progression to castration-resistant prostate cancer (CRPC), was investigated in patients with metastatic castration sensitive prostate cancer (mCSPC) treated with the oral nonsteroidal antiandrogen enzalutamide. The findings are expected to contribute to the development of novel therapeutic strategies for personalized medicine in prostate cancer."},"methods":{"ja":"Whole exome sequencing解析","en":"Whole exome sequencing analysis"},"targets":{"ja":"mCSPC診断時（エンザルタミド投与前）に取得された前立腺生検標本","en":"76 mCSPCs prior to enzalutamide treatment"},"url":{"ja":[{"url":"https://www.osaka-urology.jp/files/1064.pdf","text":"https://www.osaka-urology.jp/files/1064.pdf"}],"en":null}},"listingSummary":{"methods":{"ja":"配列決定","en":"Sequencing"},"targets":{"ja":"mCSPC：76症例\n（日本人）","en":"mCSPC: 76 cases\n(Japanese)"},"typeOfData":{"ja":"NGS\n（Exome）","en":"NGS\n(Exome)"}},"releaseNote":{"ja":"エンザルタミド投与を受けた転移性去勢感受性前立腺がん（mCSPC）76症例のFFPE前立腺生検標本の腫瘍組織76検体、ならびに、末梢血76検体から抽出したDNAを用いたwhole exome sequencing解析データをfastqファイルにて提供する。","en":"DNAs extracted from FFPE prostate biopsy specimens obtained at diagnosis prior to enzalutamide treatment and matched samples extracted from peripheral blood cells from 76 patients with mCSPC were used for the whole exome sequencing analysis. Fastq files are provided."},"dataProviders":[{"name":{"ja":"波多野 浩士","en":"Koji Hatano"},"organization":{"name":{"ja":"大阪大学大学院医学系研究科 泌尿器科","en":"Department of Urology, The University of Osaka Graduate School of Medicine"}}}],"researchProjects":[{"name":{"ja":"MENZ studyグループ","en":"MENZ study group"},"url":{"ja":null,"en":null}}],"grants":[{"title":{"ja":"エンザルタミドの投与を受けている転移性去勢感受性前立腺癌（mCSPC）患者における癌ゲノムと臨床転帰の関連について検討する多施設前向き研究","en":"A Prospective Multicenter Study of Exploring Genomic Correlates of Clinical Outcome in Patients with Metastatic Castration-Sensitive Prostate Cancer Receiving Enzalutamide"},"agency":{"ja":"Cancer Clinical Research Grant Program","en":"Cancer Clinical Research Grant Program"},"grantIds":null},{"title":{"ja":"エンザルタミドの投与を受けている転移性去勢感受性前立腺癌（mCSPC）患者における癌ゲノムと臨床転帰の関連について検討する多施設前向き研究","en":"A Prospective Multicenter Study of Exploring Genomic Correlates of Clinical Outcome in Patients with Metastatic Castration-Sensitive Prostate Cancer Receiving Enzalutamide"},"agency":{"ja":"Astellas funding","en":"Astellas funding"},"grantIds":null}],"relatedPublications":[],"datasets":["JGAD001046"],"controlledAccessUsers":[]}